【摘要】 目的分析含硼替佐米的化疗对多发性骨髓瘤(MM)的疗效及不良反应。方法随机抽取60例江门市新会区人民医院2014年1月-2017年1月收治的MM患者,根据不同的治疗方法将其分为对照组、治疗组各30例,对照组应用COMP方案(环磷酰胺+VCR+美法仑+强的松),治疗组应用BD方案(硼替佐米+地塞米松),观察两组治疗总有效率及不良反应。结果治疗组总有效率为93.3%,高于对照组的73.3%,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论应用含硼替佐米的化疗方案能有效提高MM的临床疗效,且安全性较高,值得临床推广。更多还原

【Abstract】 Objective To analyze the efficacy and adverse reactions of chemotherapy with bortezomib in multiple myeloma(MM).Methods Sixty patients with MM who were admitted to Jiangmen Xinhui District People’s Hospital from January 2014 to January 2017 were randomly divided into control group and treatment group with 30 cases in each group.The control group was treated with COMP regimen(Cyclophosphamide +VCR +Melalon +Prednisone).The treatment group was treated with BD regimen(Bortezomizomi+Dexamethasone).The total effective rate and the adverse reactions in the two groups were analyzed.Results The total effective rate of the treatment group was 93.3%,higher than that of the control group with 73.3%,the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P >0.05).Conclusion The chemotherapy regimen of containing bortezomib can effectively improve the clinical efficacy of MM,and it is safe and worthy of clinical promotion.更多还原